Phosphopeptide Neoantigens in Cancer Immunotherapy
Author Information
Author(s): Apoorvi Tyagi, Yury Patskovsky, Iryna Voloshyna, Michelle Krogsgaard
Primary Institution: NYU Grossman School of Medicine
Hypothesis
Phosphorylated peptides (p-peptides) can serve as novel targets for cancer immunotherapy.
Conclusion
Phosphorylated peptides are emerging as a promising class of tumor-specific antigens that could enhance cancer immunotherapy.
Supporting Evidence
- Phosphorylated antigens can provide a diverse range of immune targets, reducing the chance of tumor immune escape.
- Studies have shown that p-peptides can elicit strong immune responses in cancer patients.
- Phosphorylation can enhance the stability and binding of peptides to MHC molecules, improving their immunogenicity.
Takeaway
Scientists are studying special proteins called phosphopeptides that can help the body fight cancer better. These proteins are like superhero badges that show the immune system where to attack.
Methodology
The review summarizes existing literature on phosphopeptide neoantigens and their mechanisms of immunogenicity.
Limitations
Further research is needed to fully understand the role of p-peptides in tumor progression and their safety in clinical applications.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website